CellSpot™ has achieved a qualitative advance over earlier methods of antibody screening by integrating the past decade's two dominant trends in assay design: multiplexing and miniaturization. Multiplexing enables the discovery of higher quality antibodies but the resulting clone frequency is so low that miniaturization is needed make screening cost effective. CellSpot™ enables screening millions of individual antibody variants produced by millions of individual antibody producing cells. The technology and lead application are described in the following publications.
Multiplexed Elispot assay.
This publication describes the basic assay of secreted proteins from single cells, with multiplexed detection.
Harriman WD, Collarini EJ, Cromer RG, Dutta A, Strandh M, Zhang F, Kauvar LM. ” J Immunol Methods 341(1-2):127-34 (2009)
Antibody discovery via multiplexed single cell characterization.
This publication describes the application of the multiplexed single cell assay to the discovery of monoclonal antibodies from murine hybridoma libraries.
Harriman WD, Collarini EJ, Sperinde GV, Strandh M, Fatholahi MM, Dutta A, Lee Y, Mettler SE, Keyt BA, Ellsworth SL, Kauvar LM. J Immunol Methods 341(1-2):135-45 (2009).
Potent High-Affinity Antibodies for Treatment
and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of
This publication describes the application of the multiplexed single cell assay to the discovery of monoclonal antibodies from human B lymphocytes. It further describes the initial biological characterization of the lead antibody against RSV (Respiratory Syncytial Virus).
Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM. J Immunol 2009 [Epub Oct 19].
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus G protein mediates virus clearance and reduces RSV pathogenesis in BALB/c mice.
This publication describes biological characterization of a murine monoclonal antibody with the same specificity as the Trellis lead human antibody.
Haynes LM, Caidi H, Radu GU et al. J. Infect. Dis. 2009; 200(3):439-447.
Treatment with respiratory syncytial virus G
glycoprotein monoclonal antibody or F(ab')2 components mediate reduced
pulmonary inflammation in mice.
This publication extends the analysis of the murine homolog to the Trellis lead human antibody to highlight two distinct mechanisms of action: direct antiviral activity; and restoration of the host immune response that is disrupted by the virus.
Miao C, Radu GU, Caidi H et al. J Gen Virol 2009; 90:1119-23.